on Exxel Pharma, Inc.
Exxel Pharma to Join "New to Virtual Investor" Event
Exxel Pharma, a pharmaceutical company from Aurora, Colorado, will participate in a "New to Virtual Investor" segment on February 5, 2025, at 4:00 PM ET. This event will feature Dr. Soren Mogelsvang, the company's CEO, who will present a corporate overview and future business plans.
The live webcast will be available on Exxel Pharma's website and the Virtual Investor platform. Participants will have the opportunity to ask questions during the event, which Exxel Pharma aims to address as time permits.
Exxel Pharma is focused on developing treatments for neuronal hypersensitivity disorders. Their lead project, EX937, is an orally administered molecule targeting refractory chronic cough. Initial studies have shown promising results without central side effects.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Exxel Pharma, Inc. news